Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hanesbrands (HBI) downgraded to Equal Weight from Overweight at Barclays with analyst Chethan Mallela saying he sees a lack of visibility into the second half of the year following the company's Q2 results. 2. Royal Dutch Shell (RDS.A) downgraded to Equal Weight from Overweight at Morgan Stanley. 3. Verisk Analytics (VRSK) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Arash Soleimani citing valuation. 4. People's Utah Bancorp (PUB) downgraded to Market Perform at Raymond James with analyst David Long citing valuation. 5. Wendy's (WEN) downgraded to Neutral ahead of Q2 report at Kalinowski with analyst Mark Kalinowski saying his checks indicate July same-store-sales are trending below the +1.5% level and were the worst checks since February 2012. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Agilent Technologies announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In vitro diagnostic devices, which include pregnancy tests, COVID-19 tests, urine test strips, and more, are estimated to play a part in 70% of all diagnostic decisions. The EU has introduced the IVDR regulatory framework to ensure the safety and performance of these devices. Under the new rules, in vitro diagnostic devices are subject to more stringent regulatory scrutiny to ensure rigorous standards of clinical evidence are met, with greater transparency and tighter standardization. The GenetiSure Dx Postnatal Assay uses Agilent's proprietary array Comparative Genomic Hybridization, aCGH, to identify copy-number and copy-neutral changes across the genome, enabling cytogeneticists to accurately assess genetic anomalies associated with developmental delay, intellectual disability, congenital anomalies, and dysmorphic features. The assay is based on chromosomal microarray technology with a firmly established track record of diagnostic accuracy and ease of use. Bob McMahon, interim president of Agilent's Diagnostics and Genomics Group, commented on this announcement. "The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test. With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU."